Abstract: A composition for a formulation additive that is water free that can be added to a formulation or other solution to increase its sanitizing persistence capabilities. The composition can include, by weight, from about 20% to about 70% cyclomethicone; from about 16% to about 35% quaternary ammonium salt; from about 16% to about 50% solvent; and from about 0% to about 35% emulsifier.

Abstract: A composition for a formulation additive that is water free that can be added to a formulation or other solution to increase its sanitizing persistence capabilities. The composition can include, by weight, from about 20% to about 70% cyclomethicone; from about 16% to about 35% quaternary ammonium salt; from about 16% to about 50% solvent; and from about 0% to about 35% emulsifier.

Abstract: A waterless and essentially alcohol-free sanitizer composition or aerosolized hand sanitizing composition containing a quaternary ammonium salt such as benzalkonium chloride to kill germs and bacteria, a volatile carrier such as cyclomethicone, additional moisturizers, and optionally fragrance or other additives.

Abstract: A waterless and essentially alcohol-free sanitizer composition or aerosolized hand sanitizing composition containing a quaternary ammonium salt such as benzalkonium chloride to kill germs and bacteria, a volatile carrier such as cyclomethicone, additional moisturizers, and optionally fragrance or other additives.

Abstract: The present invention provides methods of treating heart failure and improving renal function, and/or preventing the advancement of heart failure into advanced stages, and methods of counteracting ischemia due to a myocardial infarction by providing improved methods of administering a therapeutically effective amount CGRP as a controlled release formulation. The therapies can be administered on an outpatient or inpatient basis and can further be used as maintenance therapies.

Abstract: The present invention provides methods of treating heart failure and improving renal function, and/or preventing the advancement of heart failure into advanced stages, and methods of counteracting ischemia due to a myocardial infarction by providing improved methods of administering a therapeutically effective amount CGRP as a controlled release formulation. The therapies can be administered on an outpatient or inpatient basis and can further be used as maintenance therapies.

Abstract: This invention relates to methods of treating acute myocardial infarction by administering calcitonin gene related peptide (CGRP). This invention also relates to preventing an acute myocardial infarction by administering calcitonin gene related peptide (CGRP). This invention further relates to compositions of CGRP for use in such methods. This invention also relates to the use of calcitonin gene related peptide in the manufacture of medicament for treating or preventing an acute myocardial infarction in a subject or for treating a subject suspected of having an acute myocardial infarction.

Abstract: The present invention provides methods of treating heart failure and improving renal function, and/or preventing the advancement of heart failure into advanced stages, and methods of counteracting ischemia due to a myocardial infarction by providing improved methods of administering a therapeutically effective amount CGRP as a controlled release formulation. The therapies can be administered on an outpatient or inpatient basis and can further be used as maintenance therapies.

Abstract: The present invention provides a method and composition for the treatment of Female Sexual Arousal Disorder. Calcitonin gene-related peptide, a naturally occurring substance in the human body, is chemically conjugated to a hydrophobic agent thereby increasing its permeability across the skin membrane. When locally applied to female genitalia localized blood flow is promoted thus resulting in increased sexual arousal.

Abstract: The present invention provides a method and composition for the treatment of Female Sexual Arousal Disorder. Calcitonin gene-related peptide, a naturally occurring substance in the human body, is chemically conjugated to a hydrophobic agent thereby increasing its permeability across the skin membrane. When locally applied to female genitalia localized blood flow is promoted thus resulting in increased sexual arousal.

Abstract: The invention is directed to a polymer formulation in which a pharmaceutically acceptable, biocompatible, biodegradable and/or bioerodible, water-coagulable thermoplastic polymer or copolymer which is substantially insoluble in an aqueous medium is dissolved in .epsilon.-caprolactone, a pharmaceutically-acceptable, moderately water-soluble organic solvent. When brought in contact with an aqueous environment, such as body or tissue fluids, the .epsilon.-caprolactone slowly dissipates into the aqueous fluid. As the .epsilon.-caprolactone dissipates, the water-insoluble thermoplastic polymer coagulates to form a flexible matrix. Preferably, the thermoplastic polymer is a copolymer of caprolactone or methylene carbonate and lactide or glycolide monomers. More preferably, the thermoplastic polymer is poly(DL-lactide-co-caprolactone). The polymer formulation may also contain a biologically active agent and/or a rate modifying agents to control the rate of release of the biologically active agent.

Abstract: The invention provides an apparatus for remote delivery of an aerosolized liquid by laparoscopic technique, a method of delivering an aerosolized liquid into the body of an animal by means of the apparatus, and a kit that contains components of the apparatus.

Abstract: A medical device which is a surgically implantable device coated with an adjunctive polymer system. The adjunctive polymer system forms a solid matrix when introduced into a human or animal body. The adjunctive polymer system can contain a drug or a medicament which is released over time from the solid matrix. The adjunctive polymer system contacts body tissue into which the surgically implantable device is implanted.

Abstract: A medical device which is a surgically implantable device coated with an adjunctive polymer system. The adjunctive polymer system forms a solid matrix when introduced into a human or animal body. The adjunctive polymer system can contain a drug or a medicament which is released over time from the solid matrix. The adjunctive polymer system contacts body tissue into which the surgically implantable device is implanted.